Status
Conditions
Treatments
About
Ongoing laboratory work into the pathology of Leukaemia:
Full description
The investigators will test AML samples sent to the diagnostic laboratory from participants with newly diagnosed or relapsed/refractory AML. Samples will be sent from district general hospitals and teaching hospitals.
Results will be returned to referring clinicians in the same way investigators currently return results for samples sent for standard tests. The service will be advertised through the Royal Marsden Website with visibility to both participants and HCPs). The investigators will also inform all the clinicians involved in the AML working party (Dr Taussig is a member of the AML working group).
In addition we are looking at diagnostic approaches to IDH 1 and 2 mutation identification.
An initial comparison of 50 samples by three analysis methods will be conducted.
IDH1 and IDH2 variant discovery will first be performed using an established standard in house SOP (SOP: SMD103) for CE-SSCA
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
18 & Over Diagnosis of AML Generic Research consent given
Exclusion criteria
Under 18 No generic research consent
Loading...
Central trial contact
Leonora Conneely
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal